Hints and tips:
Related Special Reports
...Roughly a quarter of the funding comes via an equity investment, with the remainder composed of research grants and commitments for joint business development that will not dilute shareholders, said people...
...The Development Bank of Japan said it wanted to connect the country’s start-ups with others across the world....
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...other drug development....
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...One of his most well-known contributions to research is the ‘Sally-Anne task’....
...Dr Matthew Hobbs, director of research at Prostate Cancer UK, said such changes had “made the process safer and more accurate” but better evidence was needed to understand their full impact....
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
...The role of Einstein’s general theory of relativity in the development of the Global Positioning System that had revolutionised navigation was a “great example”, he said....
...Martin Holst Lange, head of development at Novo Nordisk, said that Cardior’s drug had the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people...
...not involved in the research....
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...In 2022/23, NIHR research expenditure for all cancers was £121.8mn.”...
...Over the past year or so, the rapid development of artificial intelligence has sparked trepidation over how it may disrupt various facets of the modern world — from job security to the development of new...
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
Breakthrough medicine will now be subject to further review by committee of independent experts
...But pills are the holy grail of convenience, making them a key development in the next generation of weight-loss drugs....
...He sold off assets in non-core areas to invest heavily in research and development, plus fund acquisitions. There were setbacks, including criticism over its accounting practices....
...“There is an issue of duplication, where too many funds seem to be chasing similar prospects . . . without co-ordinating their investments,” said Bright Simons, vice-president of research at Ghanaian think-tank...
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
...“The development of this theory was a massive conceptual leap from a brilliant mind.”...
International Edition